The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Christian H Geisler; Arne Kolstad; Anna Laurell; Riikka Räty; Mats Jerkeman; Mikael Eriksson; Marie Nordström; Eva Kimby; Anne Marie Boesen; Herman Nilsson-Ehle; Outi Kuittinen; Grete F Lauritzsen; Elisabeth Ralfkiaer; Mats Ehinger; Christer Sundström; Jan Delabie; Marja-Liisa Karjalainen-Lindsberg; Peter Brown; Erkki Elonen; Nordic Lymphoma Group

doi:10.1182/blood-2009-08-236570

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

Christian H Geisler, Arne Kolstad, Anna Laurell, Riikka Räty, Mats Jerkeman, Mikael Eriksson, Marie Nordström, Eva Kimby, Anne Marie Boesen, Herman Nilsson-Ehle, Outi Kuittinen, Grete F Lauritzsen, Elisabeth Ralfkiaer, Mats Ehinger, Christer Sundström, Jan Delabie, Marja-Liisa Karjalainen-Lindsberg, Peter Brown, Erkki Elonen, Nordic Lymphoma Group

132 Citationer (Scopus)

Abstract

Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCLbetter than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPI_B (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.

Originalsprog	Engelsk
Tidsskrift	Blood
Vol/bind	115
Udgave nummer	8
Sider (fra-til)	1530-3
Antal sider	4
ISSN	0006-4971
DOI	https://doi.org/10.1182/blood-2009-08-236570
Status	Udgivet - 25 feb. 2010

Adgang til dokumentet

10.1182/blood-2009-08-236570

http://www.bloodjournal.org/content/bloodjournal/115/8/1530.full.pdf

Fingeraftryk

Dyk ned i forskningsemnerne om 'The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Geisler, C. H., Kolstad, A., Laurell, A., Räty, R., Jerkeman, M., Eriksson, M., Nordström, M., Kimby, E., Boesen, A. M., Nilsson-Ehle, H., Kuittinen, O., Lauritzsen, G. F., Ralfkiaer, E., Ehinger, M., Sundström, C., Delabie, J., Karjalainen-Lindsberg, M-L., Brown, P., Elonen, E., & Nordic Lymphoma Group (2010). The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 115(8), 1530-3. https://doi.org/10.1182/blood-2009-08-236570

The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). / Geisler, Christian H; Kolstad, Arne; Laurell, Anna et al.

I: Blood, Bind 115, Nr. 8, 25.02.2010, s. 1530-3.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Geisler, CH, Kolstad, A, Laurell, A, Räty, R, Jerkeman, M, Eriksson, M, Nordström, M, Kimby, E, Boesen, AM, Nilsson-Ehle, H, Kuittinen, O, Lauritzsen, GF, Ralfkiaer, E, Ehinger, M, Sundström, C, Delabie, J, Karjalainen-Lindsberg, M-L, Brown, P, Elonen, E & Nordic Lymphoma Group 2010, 'The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)', Blood, bind 115, nr. 8, s. 1530-3. https://doi.org/10.1182/blood-2009-08-236570

Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood. 2010 feb. 25;115(8):1530-3. doi: 10.1182/blood-2009-08-236570

@article{ebf52652b94e416c947db245431fcad6,

title = "The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)",

abstract = "Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCLbetter than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.",

author = "Geisler, {Christian H} and Arne Kolstad and Anna Laurell and Riikka R{\"a}ty and Mats Jerkeman and Mikael Eriksson and Marie Nordstr{\"o}m and Eva Kimby and Boesen, {Anne Marie} and Herman Nilsson-Ehle and Outi Kuittinen and Lauritzsen, {Grete F} and Elisabeth Ralfkiaer and Mats Ehinger and Christer Sundstr{\"o}m and Jan Delabie and Marja-Liisa Karjalainen-Lindsberg and Peter Brown and Erkki Elonen and Ralfki{\ae}r, {Elisabeth Methner}",

year = "2010",

month = feb,

day = "25",

doi = "10.1182/blood-2009-08-236570",

language = "English",

volume = "115",

pages = "1530--3",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "8",

}

TY - JOUR

T1 - The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)

AU - Geisler, Christian H

AU - Kolstad, Arne

AU - Laurell, Anna

AU - Räty, Riikka

AU - Jerkeman, Mats

AU - Eriksson, Mikael

AU - Nordström, Marie

AU - Kimby, Eva

AU - Boesen, Anne Marie

AU - Nilsson-Ehle, Herman

AU - Kuittinen, Outi

AU - Lauritzsen, Grete F

AU - Ralfkiaer, Elisabeth

AU - Ehinger, Mats

AU - Sundström, Christer

AU - Delabie, Jan

AU - Karjalainen-Lindsberg, Marja-Liisa

AU - Brown, Peter

AU - Elonen, Erkki

AU - Nordic Lymphoma Group

PY - 2010/2/25

Y1 - 2010/2/25

N2 - Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCLbetter than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.

AB - Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCLbetter than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.

U2 - 10.1182/blood-2009-08-236570

DO - 10.1182/blood-2009-08-236570

M3 - Journal article

SN - 0006-4971

VL - 115

SP - 1530

EP - 1533

JO - Blood

JF - Blood

IS - 8

ER -